Is Synacor, Inc. (NASDAQ:SYNC) Overpaying Its CEO?

Syros Pharmaceuticals is a biopharmaceutical company whose headquarters is located in Watertown MA. The Syros’s shares are traded on the Nasdaq global market as NASDAQ: SYRS at The founders of this leading pharmaceutical company include Richard A Young, James E Bradner, and Nathaniel S Gray. The President and Chief Executive Officer of the firm are Nancy Simonian. The Chief Scientific Officer that looks into the research and development of medicines for cancer patients is Eric R Olson.


The firm targets diseases like Acute Myeloid leukaemia (AML) which is a cancer of the blood. It also focuses on creating treatment in terms of medicines for diseases like advanced breast cancer, colorectal cancer, lung, and ovarian cancer. At their research centre, scientists believe that genes alter the proper functioning of cells. This invariably leads to severe life-threatening diseases. Their gene control platform aims at identifying and isolating the cells from the person’s tissues and performing different treatments on them. The scientists focus on the regulation of genes, disease biology, and small molecular chemistry to thoroughly understand the disease-causing cells. Hence the outcome of the medicines is studied after performing varied tests on the cells.


Presently the pharmaceutical company runs 2 clinical programs SY-1425(Acute Myeloid Leukemia) and SY-5609 for Select Solid Tumors. There are nearly 30,000 patients every year that suffer from Acute Myeloid leukaemia with fewer survival chances despite drugs and therapies. The programs focus on the cancer patients that do not respond well even to chemotherapy or medication. Global Blood Therapeutics partners with syrs that aims at making an oral medicine for life-threatening diseases like beta-thalassemia and sickle cell disease. Incyte Corporation is its second partner that works along with Syros Pharmaceuticals in creating therapies for myeloproliferative neoplasms. The firm extensively works on discovering new medication and therapies for diseases that are closely related to abnormal cell functioning. Hence if the clinical trials are successful the path to recovery and treatment seems positive for cancer and thalassemia patients.


The company strives to incorporate technological advancement to genome study. This improves the chances of creating progressive drugs and treatments for diseases like cancer and sickle cell diseases. Syrs believes in diversity and inclusion and includes thousands of researchers across the globe to be a part of their ongoing medical mission. Technological innovations in the area of science and discovery are closely observed by scientists. It believes in good partnership with new research centres around to create and bring effective treatments for diseases that can be genetically changed and treated. You can check more stock news during stocks after hours.


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.